Pharmacokinetics of high-dose carboplatin in children undergoing high-dose chemotherapy and autologous stem cell transplantation with BSA-based dosing

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Bone Marrow Transplantation

• Publication date

  2019-08-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41409-019-0655-5PMID 31462686
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

  2017cited by this paper
• High-dose chemotherapy and autologous stem cell transplantation with melphalan, etoposide and carboplatin for high-risk osteosarcoma

  2015cited by this paper
• Extra-cranial Malignant Rhabdoid Tumor in Children: A Single Institute Experience

  2014cited by this paper
• Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: Results of SMC NB-2004 study

  2013cited by this paper
• Myeloablative chemotherapy and autologous stem cell transplantation in patients with relapsed or progressed central nervous system germ cell tumors: results of Korean Society of Pediatric Neuro-Oncology (KSPNO) S-053 study

  2013cited by this paper
• Adaptive dosing and platinum–DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours

  2007cited by this paper
• Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients

  2004cited by this paper
• Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer

  2003cited by this paper
• Estimation of glomerular filtration rate in cancer patients

  2001cited by this paper
• Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods

  2000cited by this paper
• Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level.

  2000cited by this paper
• Calvert's formula for dosing carboplatin: overview and concerns of applicability in high-dose setting.

  2000cited by this paper
• Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.

  2000cited by this paper
• A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage.

  2000cited by this paper
• Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial.

  2000cited by this paper
• Clinical Pharmacokinetics and Dose Optimisation of Carboplatin

  1997cited by this paper
• Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.

  1996cited by this paper
• Population pharmacokinetics of carboplatin in children

  1996cited by this paper
• Prediction of carboplatin clearance from standard morphological and biological patient characteristics.

  1995cited by this paper
• High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.

  1994cited by this paper
• Carboplatin in pediatric malignancies.

  1994cited by this paper
• Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.

  1993cited by this paper
• High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer.

  1993cited by this paper
• Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group.

  1993cited by this paper
• Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.

  1993cited by this paper
• Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.

  1992cited by this paper
• Clinical Pharmacokinetics of Carboplatin

  1991cited by this paper
• A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.

  1991cited by this paper
• Clinical pharmacokinetics of carboplatin.

  1991cited by this paper
• A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.

  1989cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Clinical Pharmacokinetics of Carboplatin

  1988cited by this paper
• Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin.

  1987cited by this paper
• Pharmacokinetics of diammine(l,l cyclobutanedi carboxylato) platinum(II) (carboplatin) after intravenous administration

  1987cited by this paper
• Pharmacokinetics of carboplatin after i.v. administration.

  1987cited by this paper
• High-dose carboplatin in refractory ovarian cancer patients.

  1987cited by this paper
• Prediction of Creatinine Clearance from Serum Creatinine

  1976cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper
• Letter: Creatinine clearance: bedside estimate.

  1973cited by this paper
• Creatinine Clearance: Bedside Estimate

  1973cited by this paper

• Protective effect of vasostatin-1 plasmid-like nanoparticles on aortic aneurysm and its mechanism

  2021cites this paper